About Pain Therapeutics (NASDAQ:PTIE)
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:PTIE
- CUSIP: 69562K10
- Web: www.paintrials.com
- Market Cap: $24.67 million
- Outstanding Shares: 6,595,000
- 50 Day Moving Avg: $3.97
- 200 Day Moving Avg: $4.15
- 52 Week Range: $3.10 - $9.31
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.29
- P/E Growth: -0.020
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.01 per share
- Price / Book: 1.86
- EBITDA: ($12,950,000.00)
- Return on Equity: -75.11%
- Return on Assets: -70.30%
- Current Ratio: 14.21%
- Quick Ratio: 14.21%
- Average Volume: 40,232 shs.
- Beta: 2.14
- Short Ratio: 15.2
Frequently Asked Questions for Pain Therapeutics (NASDAQ:PTIE)
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?
Shares of Pain Therapeutics reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.
How were Pain Therapeutics' earnings last quarter?
Pain Therapeutics (NASDAQ:PTIE) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.17. View Pain Therapeutics' Earnings History.
Who are some of Pain Therapeutics' key competitors?
Some companies that are related to Pain Therapeutics include Bellerophon Therapeutics (BLPH), Avacta Group Plc (AVCT), pSivida Corp. (PSDV), Alcobra (ADHD), Aldeyra Therapeutics (ALDX), Proteon Therapeutics (PRTO), Imprimis Pharmaceuticals (IMMY), Auris Medical Holding AG (EARS), Redx Pharma PLC (REDX), Aviragen Therapeutics (AVIR), ANGLE plc (AGL), Zosano Pharma Corporation (ZSAN), Celsion Corporation (CLSN), Egalet Corporation (EGLT), Orexigen Therapeutics (OREX), Vical Incorporated (VICL), Midatech Pharma PLC (MTPH) and Xenetic Biosciences (XBIO).
Who are Pain Therapeutics' key executives?
Pain Therapeutics' management team includes the folowing people:
- Remi Barbier, Chairman of the Board, President, Chief Executive Officer
- Nadav Friedmann, Chief Medical and Operating Officer, Director
- Michael Marsman Pharm.D., Senior Vice President - Regulatory Affairs
- Robert Z. Gussin Ph.D., Independent Director
- Michael J. O' Donnell Esq., Independent Director
- Saira Ramasastry, Independent Director
- Sanford R. Robertson, Independent Director
- Patrick J. Scannon M.D., Ph.D., Independent Director
How do I buy Pain Therapeutics stock?
Shares of Pain Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pain Therapeutics' stock price today?
MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Pain Therapeutics stock can currently be purchased for approximately $3.74.
Consensus Ratings for Pain Therapeutics (NASDAQ:PTIE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating|
|Consensus Rating:||Sell (Score: 1.00)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Pain Therapeutics (NASDAQ:PTIE)
Analysts' Ratings History for Pain Therapeutics (NASDAQ:PTIE)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/17/2017||Gabelli||Downgrade||Hold -> Sell||Low|
Earnings History for Pain Therapeutics (NASDAQ:PTIE)Earnings History by Quarter for Pain Therapeutics (NASDAQ PTIE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/6/2014||Q1 14||($0.42)||($0.56)||$1.96 million||View||N/A|
|2/4/2014||Q413||($0.07)||$5.04||$2.00 million||$35.24 million||View||N/A|
|10/31/2013||Q313||($0.07)||($0.14)||$2.00 million||$1.96 million||View||N/A|
|4/24/2013||Q1 2013||($0.07)||($0.07)||$2.80 million||$1.96 million||View||N/A|
|2/6/2013||Q4 2012||($0.14)||($0.56)||$2.79 million||$2.47 million||View||N/A|
Earnings Estimates for Pain Therapeutics (NASDAQ:PTIE)
Current Year EPS Consensus Estimate: $-2.3500 EPS
Next Year EPS Consensus Estimate: $-2.9000 EPS
Dividend History by Quarter for Pain Therapeutics (NASDAQ PTIE)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Pain Therapeutics (NASDAQ:PTIE)
Insider Ownership Percentage: 32.70%Insider Trades by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Institutional Ownership Percentage: 36.68%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/6/2013||Sanford Robertson||Director||Buy||50,000||$3.73||$186,500.00|| |
Headline Trends for Pain Therapeutics (NASDAQ:PTIE)
Latest Headlines for Pain Therapeutics (NASDAQ:PTIE)
Loading headlines, please wait.
Pain Therapeutics (PTIE) Chart for Tuesday, October, 24, 2017